Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/075—Ethers or acetals
  • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
  • A61K33/10—Carbonates; Bicarbonates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
  • A61K33/12—Magnesium silicate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• the present invention relates to a remedy for internal use, in particular against cancer.
• This problem is solved by a remedy with a proportion of minerals with a grain size of 1 to 150, in particular 1 to 20 nanometers.
• the special feature of the invention is that the extremely finely divided minerals have an extremely small diameter. They are so finely divided that they do not remain superficially on a tumor and are therefore filtered off, but can penetrate into it.
• the diameter of the minerals is smaller than the diameter of a skin pore.
• the effect of silicon according to the invention only results if it is in finely divided bioactive form, that is to say as nanoparticles. This is achieved by grinding the previously chemophysically processed silicon acid into a liquid substance in which the particles do not settle and therefore no molecular accumulation can take place.
• This colloidal silicon is similar to the albinoid arrangement of raw protein (without being sticky). It is similar to blood plasma.
• the colloidal distribution of the silicon considerably facilitates the penetration into the tissue and the bioactive interaction between the human metabolism and the individual silicon particles because of the large absorbent surface.
• the colloidal distribution and arrangement ensures not only outer boundary surfaces between liquid and air, but also between silicon and the water molecules. In this way, the silicon has surface activity and internal stress energies that have a unique activating effect in the biological processes. It is suitable for internal and external application.
• Raw silicon is obtained from sand and coal, which is further processed into the desired silicones in a continuous process.
• Natural gas or crude oil are used to produce methanol (synthesis gas), another starting material for silicone synthesis.
• Chlorine is obtained by electrolysis of rock salt solutions and is added to the process in the form of HC1.
• the remedy according to the invention can advantageously be supplemented by water, oil (mineral oil or vegetable oil) or alcohol.
• oil mineral oil or vegetable oil
• alcohol in the case of an aqueous solution, about 60% by weight of water in the end product has been found to be proven suitable.
• Vegetable oil is particularly advantageous as an oil, for example safflower oil, since it has no laxative effect when taken.
• An emulsion of polydimethylsiloxane and water is also possible.
• the mineral remedy according to the invention is advantageously produced by mixing the starting materials together in a first step. It has proven to be advantageous if the grain size of the rock powder used is already in the range of 10 micrometers or less. In a subsequent process step, the mixed components are ground using a colloid mill, the grinding duration being selected to match the desired grain size of the end product. It has proven to be advantageous if the grinding process is maintained over a period of at least 10 minutes, the use of rotor cooling of the colloid mill being indicated in order to avoid symptoms of overheating.
• the resulting mixture is a flowable gel-like liquid and can be processed into a remedy in a variety of ways. It is possible to prepare a powdery mixture by mixing the above liquid with zeolite and dolomite powder. This powder can then be supplied, for example, in the form of the widespread gelatin capsules that dissolve in the digestive tract. In addition, it is readily possible to press tablets from the powdered mixture, which can be taken with or without liquid.
• the remedy is nebulized using suitable nebulization techniques.
• suitable nebulization techniques Various devices are available for this:
• Compressed air operated Venturi nozzle nebulizer a) direct nebulization b) with aerosol reservoir c) with positive pressure inhalate
• quartz flour, dolomite stone flour and magnesium powder has proven to be particularly advantageous.
• the proportions of zeolite and dolomite can add up to 100% by weight of the weight fraction of the rock powder.
• aluminum silicate in particular natural zeolite with a grain size of 10 to 70 ⁇ m, in particular 40 ⁇ m and dolomite powder with a grain size of 2 to 30 ⁇ m, in particular 10 ⁇ m, can also be added. This results in powder that can be administered in capsules.
• the basic skeleton of the crystal lattice of the zeolite consists primarily of SiO 4 tetrahedra. It has cavities in which ions, e.g. B. are sodium, potassium and calcium, which can be easily exchanged with themselves and with their substrate environment.
• This mineral-specific crystal structure (cage structure) of zeolite has the excellent property in living organisms, toxic substances, such as. B. ammonia and other nitrogen compounds, but also heavy metals, to bind (absorb) and excrete via the intestinal metabolism. The extracted toxic substances are exchanged for minerals that the body urgently needs. Untitled. In this way, the homeostasis of the organism, in particular that of the mineral metabolism, is maintained or restored.
• sensitive organ systems e.g. B. brain, nervous system, hormonal system, immune system, liver, kidneys and. a. not only protected from toxic damage, but also increased their resistance to harmful pathogenic influences
• the zeolite Like the silicon, the zeolite also has a positive stimulating effect on the entire metabolism and in the growth and healing processes of the organism.
• zeolite Because of its open molecular structure, zeolite also has the ability to absorb large quantities of liquids. This is advantageous because, despite mixing with the above-mentioned components, a flowable powder can be formed.
• final grain size of the minerals in the range 1 to 100 nanometers, preferably 1 to 10 nanometers.
• the product is called Liquidum Th (with castor oil instead of vegetable oil) and is approved as a dietary supplement.
• the advantage of using vegetable oil is that the slightly laxative effect of castor oil is avoided.
• composition of an oil emulsion according to the invention with minerals and precipitated silica
• final grain size of the minerals in the range 1 to 100 nanometers, preferably 1 to 10 nanometers.
• composition of a medicinal product according to the invention as an aqueous solution with quartz powder or precipitated silica as an aqueous solution with quartz powder or precipitated silica:
• 40 - 80 60 wt% water.
• composition of a medicinal product according to the invention as an alcoholic solution with quartz powder or precipitated silica is an alcoholic solution with quartz powder or precipitated silica:
• final grain size of the minerals in the range 1 to 100 nanometers, preferably 1 to 10 nanometers.
• the mixtures from Examples 1 to 4 are first kneaded intensively in a kneader at a temperature of approximately 50 ° C. and then fed inline to a colloid mill.
• the colloid mill has cross toothing with pumping device and rotor cooling.
• the minerals are ground to a size of 10 " 9 m.
• the vegetable oil emulsifies in warm water and is stabilized by the methyl cellulose.
• cooling of the grinding head is necessary in the grinding stage.
• the emulsion obtained in this way is stable and can be further diluted with water and incorporated. It has been shown that the solutions from Examples 1 to 4 are effective against cancer cells, but a coarser grinding of the minerals of 10 ⁇ m has no effect. It has also been shown that the solutions only have an effect on cancer cells, but not on healthy cells.
• composition of a powder according to the invention based on the liquid products described in Examples 2 and 3:
• aluminum silicate in particular natural zeolite with a grain size of 10 to 70, in particular 40 ⁇ m,
• dolomite powder with a grain size of 2 to 30, in particular 10 ⁇ m.

Landscapes

• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Inorganic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=33441300

Family Applications (1)

Country Status (9)

Cited By (2)

Families Citing this family (8)

Citations (9)

Family Cites Families (2)

• 2003
  • 2003-05-22 DE DE10323759A patent/DE10323759A1/de not_active Withdrawn
• 2004
  • 2004-05-18 JP JP2006529602A patent/JP2006528210A/ja not_active Withdrawn
  • 2004-05-18 US US10/558,099 patent/US20060251738A1/en not_active Abandoned
  • 2004-05-18 EP EP04733527A patent/EP1628671A1/de not_active Withdrawn
  • 2004-05-18 CA CA002525908A patent/CA2525908A1/en not_active Abandoned
  • 2004-05-18 WO PCT/DE2004/001047 patent/WO2004105777A1/de not_active Ceased
  • 2004-05-18 RU RU2005140098/15A patent/RU2005140098A/ru unknown
  • 2004-05-18 AU AU2004243523A patent/AU2004243523A1/en not_active Abandoned
  • 2004-05-18 CN CNA2004800140425A patent/CN1795002A/zh active Pending

Patent Citations (9)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events